Table 1.
Summary of cases.
| Case # | Age/sex | Primary tumor diagnosis (year), treatment | Diagnosis of metastatic uveal melanoma (MUM), site | Genomic findings | MUM treatment | Side effects | Response to immunotherapy |
|---|---|---|---|---|---|---|---|
| 1 | 68, M | 2013, brachytherapy | April 2016, liver metastases | No genetic alterations | Ipilimumab 3 mg/kg and nivolumab 1 mg/kg for three cycles, followed by nivolumab 240 mg × 2 weeks + monthly TACE until February 2017 | Autoimmune colitis | Stable disease |
| 2 | 69, M | 2014, enucleation | June 2016, pulmonary metastases | GNAQ Q209P +ve | Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles | Autoimmune colitis | Progression of disease |
| 3 | 77, M | 2014, enucleation | March 2017, liver and pulmonary metastases | GNA11 Q209L +ve, BAP +ve, MGMT +ve | Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every 2 weeks plus monthly TACE | None | Stable disease |
| 4 | 76, F | 2014, brachytherapy | June 2017, liver metastases | GNA11 Q209L +ve | Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every two weeks until November 2017 | None | Stable August 2017, POD November 2017 |
| 5 | 65, M | 2014, enucleation | August 2016, liver metastases | GNAQ Q209P +ve, MYC +ve, BAP +ve, DNMT3A +ve, low mutational burden | Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks followed by nivolumab 240 mg every 2 weeks plus TACE from January 2017 | None | Partial response |
| 6 | 63, M | 2016, enucleation | February 2017, liver metastases | NA | Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg initiated in May 2017 for two cycles, followed by nivolumab 240 mg every 3 weeks plus TACE from August 2017 | Autoimmune colitis with combination | Partial response |
| 7 | 73, F | 2015, brachytherapy | September 2015, liver metastases | No genetic alterations, c-KIT +ve | TACE plus Abraxane for three cycles followed by ipilimumab 3 mg/kg plus nivolumab 1 mg/kg for one cycle in February 2017, pembrolizumab 200 mg every 3 weeks from May 2017 to September 2017 | Autoimmune colitis with combination | Progression of disease |
| 8 | 55, M | 2016, brachytherapy | June 2017, liver metastases | NA | Monthly TACE from August 2017, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every 2 weeks from December 2017 | None | Stable disease |